BRCA1 pathway function in basal-like breast cancer cells

Molecular and Cellular Biology

Volumn 34, Issue 20, 2014, Pages 3828-3842

  Hill, Sarah J ^a,b   Clark, Allison P ^b   Silver, Daniel P ^b   Livingston, David M ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; DNA; MESYLIC ACID METHYL ESTER; MITOMYCIN; OLAPARIB; SMALL INTERFERING RNA; MUTAGENIC AGENT;

ARTICLE; BASAL LIKE BREAST CANCER; BREAST CANCER CELL LINE; BREAST CELL; BREAST EPITHELIUM; CANCER CELL; CONTROLLED STUDY; DNA REPAIR; DNA REPLICATION; DOUBLE STRANDED DNA BREAK; EPITHELIUM CELL; GAMMA IRRADIATION; GENE FUNCTION; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN CELL; RADIATION EXPOSURE; TUMOR SUPPRESSOR GENE; ULTRAVIOLET IRRADIATION; BASAL CELL CARCINOMA; BREAST TUMOR; FEMALE; GENETICS; IC 50; METABOLISM; RECOMBINATION REPAIR; TUMOR CELL LINE;

BRCA1 PROTEIN; BREAST NEOPLASMS; CELL LINE, TUMOR; DNA BREAKS, DOUBLE-STRANDED; DNA REPLICATION; FEMALE; HUMANS; INHIBITORY CONCENTRATION 50; METHYL METHANESULFONATE; MUTAGENS; NEOPLASMS, BASAL CELL; RECOMBINATIONAL DNA REPAIR;

EID: 84907148216     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.01646-13     Document Type: Article

References (70)

1. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D. 2000. Molecular portraits of human breast tumours. Nature 406:747-752. http://dx.doi.org/10.1038/35021093.
2. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lonning P, Borresen-Dale AL. 2001. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. U. S. A. 98:10869- 10874. http://dx.doi.org/10.1073/pnas.191367098.
3. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lonning PE, Brown PO, Borresen-Dale AL, Botstein D. 2003. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl. Acad. Sci. U. S. A. 100:8418-8423. http://dx.doi.org/10.1073/pnas.0932692100.
4. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH. 2002. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530-536. http://dx.doi.org/10.1038/415530a.
5. Breast Cancer Linkage Consortium. 1997. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Lancet 349:1505-1510. http://dx.doi.org/10.1016/S0140-6736(96)10109-4.
6. Lakhani SR, Van De Vijver MJ, Jacquemier J, Anderson TJ, Osin PP, McGuffog L, Easton DF. 2002. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J. Clin. Oncol. 20:2310-2318. http://dx.doi.org/10.1200/JCO.2002.09.023.
7. Lakhani SR, Reis-Filho JS, Fulford L, Penault-Llorca F, van der Vijver M, Parry S, Bishop T, Benitez J, Rivas C, Bignon YJ, Chang-Claude J, Hamann U, Cornelisse CJ, Devilee P, Beckmann MW, Nestle-Kramling C, Daly PA, Haites N, Varley J, Lalloo F, Evans G, Maugard C, Meijers-Heijboer H, Klijn JG, Olah E, Gusterson BA, Pilotti S, Radice P, Scherneck S, Sobol H, Jacquemier J, Wagner T, Peto J, Stratton MR, McGuffog L, Easton DF. 2005. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin. Cancer Res. 11:5175-5180. http://dx.doi.org/10.1158/1078-0432.CCR-04 -2424.
8. Crook T, Brooks LA, Crossland S, Osin P, Barker KT, Waller J, Philp E, Smith PD, Yulug I, Peto J, Parker G, Allday MJ, Crompton MR, Gusterson BA. 1998. p53 mutation with frequent novel condons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumours. Oncogene 17:1681-1689. http://dx.doi.org/10.1038/sj.onc.1202106.
9. Manie E, Vincent-Salomon A, Lehmann-Che J, Pierron G, Turpin E, Warcoin M, Gruel N, Lebigot I, Sastre-Garau X, Lidereau R, Remenieras A, Feunteun J, Delattre O, de The H, Stoppa-Lyonnet D, Stern MH. 2009. High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors. Cancer Res. 69:663-671. http://dx.doi.org/10.1158/0008-5472.CAN-08-1560.
10. Valentin MD, da Silva SD, Privat M, Alaoui-Jamali M, Bignon YJ. 2012. Molecular insights on basal-like breast cancer. Breast Cancer Res. Treat. 134:21-30. http://dx.doi.org/10.1007/s10549-011-1934-z.
11. Tammaro C, Raponi M, Wilson DI, Baralle D. 2012. BRCA1 exon 11 alternative splicing, multiple functions and the association with cancer. Biochem. Soc. Trans. 40:768-772. http://dx.doi.org/10.1042/BST20120140.
12. Boulton SJ, Martin JS, Polanowska J, Hill DE, Gartner A, Vidal M. 2004. BRCA1/BARD1 orthologs required for DNA repair in Caenorhabditis elegans. Curr. Biol. 14:33-39. http://dx.doi.org/10.1016/j.cub.2003.11.029.
13. Nakuci E, Mahner S, Direnzo J, ElShamy WM. 2006. BRCA1-IRIS regulates cyclin D1 expression in breast cancer cells. Exp. Cell Res. 312: 3120-3131. http://dx.doi.org/10.1016/j.yexcr.2006.06.021.
14. ElShamy WM, Livingston DM. 2004. Identification of BRCA1-IRIS, a BRCA1 locus product. Nat. Cell Biol. 6:954-967. http://dx.doi.org/10.1038/ncb1171.
15. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, Bell R, Rosenthal J, Hussey C, Tran T, McClure M, Frye C, Hattier T, Phelps R, Haugen-Strano A, Katcher H, Yakumo K, Gholami Z, Shaffer D, Stone S, Bayer S, Wray C, Bogden R, Dayananth P, Ward J, Tonin P, Narod S, Bristow PK, Norris FH, Helvering L, Morrison P, Rosteck P, Lai M, Barrett JC, Lewis C, Neuhausen S, Cannon-Albright L, Goldgar D, Wiseman R, Kamb A, Skolnick MH. 1994. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66-71. http://dx.doi.org/10.1126/science.7545954.
16. Silver DP, Livingston DM. 2012. Mechanisms of BRCA1 tumor suppression. Cancer Discov. 2:679-684. http://dx.doi.org/10.1158/2159-8290.CD-12-0221.
17. Li ML, Greenberg RA. 2012. Links between genome integrity and BRCA1 tumor suppression. Trends Biochem. Sci. 37:418-424. http://dx.doi.org/10.1016/j.tibs.2012.06.007.
18. Walsh T, King MC. 2007. Ten genes for inherited breast cancer. Cancer Cell 11:103-105. http://dx.doi.org/10.1016/j.ccr.2007.01.010.
19. Wu LC, Wang ZW, Tsan JT, Spillman MA, Phung A, Xu XL, Yang MC, Hwang LY, Bowcock AM, Baer R. 1996. Identification of a RING protein that can interact in vivo with the BRCA1 gene product. Nat. Genet. 14: 430-440. http://dx.doi.org/10.1038/ng1296-430.
20. Scully R, Chen J, Ochs RL, Keegan K, Hoekstra M, Feunteun J, Livingston DM. 1997. Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage. Cell 90:425-435. http://dx.doi.org/10.1016/S0092-8674(00)80503-6.
21. Scully R, Ganesan S, Vlasakova K, Chen J, Socolovsky M, Livingston DM. 1999. Genetic analysis of BRCA1 function in a defined tumor cell line. Mol. Cell 4:1093-1099. http://dx.doi.org/10.1016/S1097-2765(00)80238-5.
22. Moynahan ME, Chiu JW, Koller BH, Jasin M. 1999. Brca1 controls homology-directed DNA repair. Mol. Cell 4:511-518. http://dx.doi.org/10.1016/S1097-2765(00)80202-6.
23. Schlacher K, Wu H, Jasin M. 2012. A distinct replication fork protection pathway connects Fanconi anemia tumor suppressors to RAD51-BRCA1/2. Cancer Cell 22:106-116. http://dx.doi.org/10.1016/j.ccr.2012.05.015.
24. Pathania S, Nguyen J, Hill SJ, Scully R, Adelmant GO, Marto JA, Feunteun J, Livingston DM. 2011. BRCA1 is required for postreplication repair after UV-induced DNA damage. Mol. Cell 44:235-251. http://dx.doi.org/10.1016/j.molcel.2011.09.002.
25. Bunting SF, Callen E, Kozak ML, Kim JM, Wong N, Lopez-Contreras AJ, Ludwig T, Baer R, Faryabi RB, Malhowski A, Chen HT, Fernandez-Capetillo O, D'Andrea A, Nussenzweig A. 2012. BRCA1 functions independently of homologous recombination in DNA interstrand crosslink repair. Mol. Cell 46:125-135. http://dx.doi.org/10.1016/j.molcel.2012.02.015.
26. Garcia-Higuera I, Taniguchi T, Ganesan S, Meyn MS, Timmers C, Hejna J, Grompe M, D'Andrea AD. 2001. Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Mol. Cell 7:249-262. http://dx.doi.org/10.1016/S1097-2765(01)00173-3.
27. Vandenberg CJ, Gergely F, Ong CY, Pace P, Mallery DL, Hiom K, Patel KJ. 2003. BRCA1-independent ubiquitination of FANCD2. Mol. Cell 12: 247-254. http://dx.doi.org/10.1016/S1097-2765(03)00281-8.
28. Joukov V, Groen AC, Prokhorova T, Gerson R, White E, Rodriguez A, Walter JC, Livingston DM. 2006. The BRCA1/BARD1 heterodimer modulates ran-dependent mitotic spindle assembly. Cell 127:539-552. http://dx.doi.org/10.1016/j.cell.2006.08.053.
29. Hsu LC, Doan TP, White RL. 2001. Identification of a gamma-tubulinbinding domain in BRCA1. Cancer Res. 61:7713-7718.
30. Xu X, Weaver Z, Linke SP, Li C, Gotay J, Wang XW, Harris CC, Ried T, Deng CX. 1999. Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoformdeficient cells. Mol. Cell 3:389-395. http://dx.doi.org/10.1016/S1097 -2765(00)80466-9.
31. Zhu Q, Pao GM, Huynh AM, Suh H, Tonnu N, Nederlof PM, Gage FH, Verma IM. 2011. BRCA1 tumour suppression occurs via heterochromatin-mediated silencing. Nature 477:179-184. http://dx.doi.org/10.1038/nature10371.
32. Greenberg RA. 2008. Recognition of DNA double strand breaks by the BRCA1 tumor suppressor network. Chromosoma 117:305-317. http://dx.doi.org/10.1007/s00412-008-0154-8.
33. Huen MS, Sy SM, Chen J. 2010. BRCA1 and its toolbox for the maintenance of genome integrity. Nat. Rev. Mol. Cell Biol. 11:138-148. http://dx.doi.org/10.1038/nrm2831.
34. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, Speed T, Spellman PT, DeVries S, Lapuk A, Wang NJ, Kuo WL, Stilwell JL, Pinkel D, Albertson DG, Waldman FM, McCormick F, Dickson RB, Johnson MD, Lippman M, Ethier S, Gazdar A, Gray JW. 2006. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10:515-527. http://dx.doi.org/10.1016/j.ccr.2006.10.008.
35. Pierce AJ, Johnson RD, Thompson LH, Jasin M. 1999. XRCC3 promotes homology-directed repair of DNA damage in mammalian cells. Genes Dev. 13:2633-2638. http://dx.doi.org/10.1101/gad.13.20.2633.
36. Polo SE, Roche D, Almouzni G. 2006. New histone incorporation marks sites of UV repair in human cells. Cell 127:481-493. http://dx.doi.org/10.1016/j.cell.2006.08.049.
37. Chen J, Silver DP, Walpita D, Cantor SB, Gazdar AF, Tomlinson G, Couch FJ, Weber BL, Ashley T, Livingston DM, Scully R. 1998. Stable interaction between the products of the BRCA1 and BRCA2 tumor suppressor genes in mitotic and meiotic cells. Mol. Cell 2:317-328. http://dx.doi.org/10.1016/S1097-2765(00)80276-2.
38. Church GM, Gilbert W. 1984. Genomic sequencing. Proc. Natl. Acad. Sci. U. S. A. 81:1991-1995. http://dx.doi.org/10.1073/pnas.81.7.1991.
39. Elstrodt F, Hollestelle A, Nagel JH, Gorin M, Wasielewski M, van den Ouweland A, Merajver SD, Ethier SP, Schutte M. 2006. BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants. Cancer Res. 66:41-45. http://dx.doi.org/10.1158/0008 -5472.CAN-05-2853.
40. Bamford S, Dawson E, Forbes S, Clements J, Pettett R, Dogan A, Flanagan A, Teague J, Futreal PA, Stratton MR, Wooster R. 2004. The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br. J. Cancer 91:355-358. http://dx.doi.org/10.1038/sj.bjc.6601894.
41. Ince TA, Richardson AL, Bell GW, Saitoh M, Godar S, Karnoub AE, Iglehart JD, Weinberg RA. 2007. Transformation of different human breast epithelial cell types leads to distinct tumor phenotypes. Cancer Cell 12:160-170. http://dx.doi.org/10.1016/j.ccr.2007.06.013.
42. Oplustilova L, Wolanin K, Mistrik M, Korinkova G, Simkova D, Bouchal J, Lenobel R, Bartkova J, Lau A, O'Connor MJ, Lukas J, Bartek J. 2012. Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment. Cell Cycle 11:3837- 3850. http://dx.doi.org/10.4161/cc.22026.
43. Graeser M, McCarthy A, Lord CJ, Savage K, Hills M, Salter J, Orr N, Parton M, Smith IE, Reis-Filho JS, Dowsett M, Ashworth A, Turner NC. 2010. A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer. Clin. Cancer Res. 16:6159-6168. http://dx.doi.org/10.1158/1078 -0432.CCR-10-1027.
44. Willers H, Taghian AG, Luo CM, Treszezamsky A, Sgroi DC, Powell SN. 2009. Utility of DNA repair protein foci for the detection of putative BRCA1 pathway defects in breast cancer biopsies. Mol. Cancer Res. 7:1304-1309. http://dx.doi.org/10.1158/1541-7786.MCR-09-0149.
45. Bouwman P, Aly A, Escandell JM, Pieterse M, Bartkova J, van der Gulden H, Hiddingh S, Thanasoula M, Kulkarni A, Yang Q, Haffty BG, Tommiska J, Blomqvist C, Drapkin R, Adams DJ, Nevanlinna H, Bartek J, Tarsounas M, Ganesan S, Jonkers J. 2010. 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCABRCA1 mutated breast cancers. Nat. Struct. Mol. Biol. 17:688-695. http://dx.doi.org/10.1038/nsmb.1831.
46. Bunting SF, Callen E, Wong N, Chen HT, Polato F, Gunn A, Bothmer A, Feldhahn N, Fernandez-Capetillo O, Cao L, Xu X, Deng CX, Finkel T, Nussenzweig M, Stark JM, Nussenzweig A. 2010. 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection ofDNAbreaks. Cell 141:243-254. http://dx.doi.org/10.1016/j.cell.2010.03.012.
47. Nakada S, Yonamine RM, Matsuo K. 2012. RNF8 regulates assembly of RAD51 at DNA double-strand breaks in the absence of BRCA1 and 53BP1. Cancer Res. 72:4974-4983. http://dx.doi.org/10.1158/0008-5472.CAN-12-1057.
48. Mone MJ, Volker M, Nikaido O, Mullenders LH, van Zeeland AA, Verschure PJ, Manders EM, van Driel R. 2001. Local UV-induced DNA damage in cell nuclei results in local transcription inhibition. EMBO Rep. 2:1013-1017. http://dx.doi.org/10.1093/embo-reports/kve224.
49. Volker M, Mone MJ, Karmakar P, van Hoffen A, Schul W, Vermeulen W, Hoeijmakers JH, van Driel R, van Zeeland AA, Mullenders LH. 2001. Sequential assembly of the nucleotide excision repair factors in vivo. Mol. Cell 8:213-224. http://dx.doi.org/10.1016/S1097-2765(01)00281-7.
50. Chew HK, Doroshow JH, Frankel P, Margolin KA, Somlo G, Lenz HJ, Gordon M, Zhang W, Yang D, Russell C, Spicer D, Synold T, Bayer R, Hantel A, Stiff PJ, Tetef ML, Gandara DR, Albain KS. 2009. Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer. J. Clin. Oncol. 27:2163-2169. http://dx.doi.org/10.1200/JCO.2008.17.4839.
51. Hurley J, Reis IM, Rodgers SE, Gomez-Fernandez C, Wright J, Leone JP, Larrieu R, Pegram MD. 2013. The use of neoadjuvant platinum-based chemotherapy in locally advanced breast cancer that is triple negative: retrospective analysis of 144 patients. Breast Cancer Res. Treat. 138:783- 794. http://dx.doi.org/10.1007/s10549-013-2497-y.
52. Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q, Juul N, Leong CO, Calogrias D, Buraimoh A, Fatima A, Gelman RS, Ryan PD, Tung NM, De Nicolo A, Ganesan S, Miron A, Colin C, Sgroi DC, Ellisen LW, Winer EP, Garber JE. 2010. Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J. Clin. Oncol. 28:1145-1153. http://dx.doi.org/10.1200/JCO.2009.22.4725.
53. Sirohi B, Arnedos M, Popat S, Ashley S, Nerurkar A, Walsh G, Johnston S, Smith IE. 2008. Platinum-based chemotherapy in triple-negative breast cancer. Ann. Oncol. 19:1847-1852. http://dx.doi.org/10.1093/annonc/mdn395.
54. Staudacher L, Cottu PH, Dieras V, Vincent-Salomon A, Guilhaume MN, Escalup L, Dorval T, Beuzeboc P, Mignot L, Pierga JY. 2011. Platinum-based chemotherapy in metastatic triple-negative breast cancer: the Institut Curie experience. Ann. Oncol. 22:848-856. http://dx.doi.org/10.1093/annonc/mdq461.
55. Zhang J, Wang Z, Hu X, Wang B, Wang L, Yang W, Liu Y, Liu G, Di G, Hu Z, Wu J, Shao Z. 13 May 2014. Cisplatin and gemcitabine as the first line therapy in metastatic triple negative breast cancer. Int. J. Cancer http://dx.doi.org/10.1002/ijc.28966.
56. Alli E, Sharma VB, Sunderesakumar P, Ford JM. 2009. Defective repair of oxidative DNA damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase. Cancer Res. 69: 3589-3596. http://dx.doi.org/10.1158/0008-5472.CAN-08-4016.
57. Huber LJ, Yang TW, Sarkisian CJ, Master SR, Deng CX, Chodosh LA. 2001. Impaired DNA damage response in cells expressing an exon 11-deleted murine Brca1 variant that localizes to nuclear foci. Mol. Cell. Biol. 21:4005-4015. http://dx.doi.org/10.1128/MCB.21.12.4005-4015.2001.
58. Garcia AI, Buisson M, Bertrand P, Rimokh R, Rouleau E, Lopez BS, Lidereau R, Mikaelian I, Mazoyer S. 2011. Down-regulation of BRCA1 expression by miR-146a and miR-146b-5p in triple negative sporadic breast cancers. EMBO Mol. Med. 3:279-290. http://dx.doi.org/10.1002/emmm.201100136.
59. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, Martin NM, Jackson SP, Smith GC, Ashworth A. 2005. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434:917-921. http://dx.doi.org/10.1038/nature03445.
60. Murai J, Huang SY, Das BB, Renaud A, Zhang Y, Doroshow JH, Ji J, Takeda S, Pommier Y. 2012. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res. 72:5588-5599. http://dx.doi.org/10.1158/0008-5472.CAN-12-2753.
61. Helleday T. 2011. The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings. Mol. Oncol. 5:387- 393. http://dx.doi.org/10.1016/j.molonc.2011.07.001.
62. Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, Hirte H, Huntsman D, Clemons M, Gilks B, Yerushalmi R, Macpherson E, Carmichael J, Oza A. 2011. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, nonrandomised study. Lancet Oncol. 12:852-861. http://dx.doi.org/10.1016/S1470-2045(11)70214-5.
63. Liu JF, Tolaney SM, Birrer M, Fleming GF, Buss MK, Dahlberg SE, Lee H, Whalen C, Tyburski K, Winer E, Ivy P, Matulonis UA. 2013. A phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer. Eur. J. Cancer 49: 2972-2978. http://dx.doi.org/10.1016/j.ejca.2013.05.020.
64. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JH, de Bono JS. 2009. Inhibition of poly-(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361:123-134. http://dx.doi.org/10.1056/NEJMoa0900212.
65. Pierce A, McGowan PM, Cotter M, Mullooly M, O'Donovan N, Rani S, O'Driscoll L, Crown J, Duffy MJ. 2013. Comparative antiproliferative effects of iniparib and olaparib on a panel of triple-negative and nontriple-negative breast cancer cell lines. Cancer Biol. Ther. 14:537-545. http://dx.doi.org/10.4161/cbt.24349.
66. Bhattacharyya A, Ear US, Koller BH, Weichselbaum RR, Bishop DK. 2000. The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with theDNA cross-linking agent cisplatin. J. Biol. Chem. 275:23899-23903. http://dx.doi.org/10.1074/jbc.C000276200.
67. DelloRusso C, Welcsh PL, Wang W, Garcia RL, King MC, Swisher EM. 2007. Functional characterization of a novel BRCA1-null ovarian cancer cell line in response to ionizing radiation. Mol. Cancer Res. 5:35-45. http://dx.doi.org/10.1158/1541-7786.MCR-06-0234.
68. Westermark UK, Reyngold M, Olshen AB, Baer R, Jasin M, Moynahan ME. 2003. BARD1 participates with BRCA1 in homology-directed repair of chromosome breaks. Mol. Cell. Biol. 23:7926-7936. http://dx.doi.org/10.1128/MCB.23.21.7926-7936.2003.
69. Xu X, Qiao W, Linke SP, Cao L, Li WM, Furth PA, Harris CC, Deng CX. 2001. Genetic interactions between tumor suppressors Brca1 and p53 in apoptosis, cell cycle and tumorigenesis. Nat. Genet. 28:266-271. http://dx.doi.org/10.1038/90108.
70. Domchek SM, Tang J, Stopfer J, Lilli DR, Hamel N, Tischkowitz M, Monteiro AN, Messick TE, Powers J, Yonker A, Couch FJ, Goldgar DE, Davidson HR, Nathanson KL, Foulkes WD, Greenberg RA. 2013. Biallelic deleterious BRCA1 mutations in a woman with early-onset ovarian cancer. Cancer Discov. 3:399-405. http://dx.doi.org/10.1158/2159 -8290.CD-12-0421.